It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

The moves come as Wall Street is gearing up for December's nonfarm payrolls reading, which is scheduled to come out at 8:30 a ...

A charming Southern metro with a thriving tech sector, strong labor market and affordable housing has been crowned as America ...

San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...

These nuggets of wisdom provide a snapshot of the actionable insights needed to help fleets become more sustainable, efficient, productive, and safe.

Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a leading ...

Meanwhile, Gilead's $40 million settlement over HIV drug delays highlights new liability risks for biopharma. Both developments underscore the evolving legal landscape and its potential to reshape ...

So, every year, thousands of Indian techies move to the US with H-1B visas. In FY 2023, the Office of Homeland Security ...

Today, the Firm's portfolio of industry-leading cloud software companies represents $9 billion in combined revenue, $75 billion in aggregate enterprise value, and over 37,000 jobs. For more ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...